The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis

Menopause

Volumn 16, Issue 4, 2009, Pages 689-693

  Celiloglu, Murat ^a   Aydin, Yunus ^a   Balci, Pinar ^a   Kolamaz, Turkan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Alendronate; Atherosclerosis; Lipids.

Indexed keywords

ALENDRONIC ACID; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CALCIUM; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VITAMIN D;

ADULT; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIPID BLOOD LEVEL; POSTMENOPAUSE OSTEOPOROSIS; STATISTICAL SIGNIFICANCE;

ALENDRONATE; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BONE DENSITY CONSERVATION AGENTS; CAROTID ARTERIES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; LIPIDS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; TRIGLYCERIDES; TUNICA INTIMA; TUNICA MEDIA;

EID: 68449096839     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318194cafd     Document Type: Article

References (31)

1. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88(12 suppl): 2961-2967.
2. Reszka AA, Rodan GA. Nitrogen-containing bisphosphonate mechanism of action. Mini Rev Med Chem 2004;4:711-719.
3. Fleisch H, Russell RG, Francis MD. Diphosphonates inhibit hydrox-yapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-1264.
4. Ylitalo R, Mönkkönen J, Urtti A, Ylitalo P. Accumulation of bisphosphonates in the aorta and some other tissues of healthy and atherosclerotic rabbits. J Lab Clin Med 1996;127:200-206.
5. Ylitalo R, Kalliovalkama J, Wu X, et al. Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro. Pharmacol Toxicol 1998;83:125-131.
6. Rosenblum IY, Flora L, Eisenstein R. The effect of disodium ethane-1-hydroxy-1,1 diphosphonate (EHDP) on a rabbit model of athero-arteriosclerosis. Atherosclerosis 1975;22:411-424.
7. Koshiyama H, Nakamura Y, Tanaka S, Minamikawa J. Decrease in carotid intima-media thickness after 1-year therapy with etidronate for osteopenia associated with type 2 diabetes. J Clin Endocrinol Metab 2000;85:2793-2796.
8. Delibasi T, Emral R, Erdogan MF, Kamel N. Effects of alendronate sodium therapy on carotid intima media thickness in postmenopausal women with osteoporosis. Adv Ther 2007;24:319-325.
9. Dwyer JH, Sun P, Kwong-Fu H, Dwyer KM, Selzer RH. Automated intima-media thickness: the Los Angeles Atherosclerosis Study. Ultrasound Med Biol 1998;24:981-987.
10. Seçil M, Altay C, GülcüA, Ceçe H, Göktay AY, Diele O. Automated measurement of intima-media thickness of carotid arteries in ultrasonography by computer software. Diagn Interv Radiol 2005;11:105-108.
11. Tankó LB, Bagger YZ, Nielsen SB, Christiansen C. Does serum cholesterol contribute to vertebral bone loss in postmenopausal women? Bone 2003;32:8-14.
12. Frye MA, Melton LJ 3rd, Bryant SC, et al. Osteoporosis and calcification of the aorta. Bone Miner 1992;19:185-194.
13. Bagger YZ, Rasmussen HB, Alexandersen P, Werge T, Christiansen C, Tankó LB. PERF study group. Links between cardiovascular disease and osteoporosis in postmenopausal women: serum lipids or atherosclerosis per se? Osteoporos Int 2007;18:505-512.
14. Tankó LB, Christiansen C, Cox DA, Geiger MJ, McNabb MA, Cummings SR. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J Bone Miner Res 2005;20:1912-1920.
15. Erratum in: J Bone Miner Res 2006;21:352.
16. Tankó LB, Bagger YZ, Christiansen C. Low bone mineral density in the hip as a marker of advanced atherosclerosis in elderly women. Calcif Tissue Int 2003;73:15-20.
17. Bagger YZ, Tankó LB, Alexandersen P, Qin G, Christiansen C, Prospective Epidemiological Risk Factors Study Group. Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. J Intern Med 2006;259:598-605.
18. Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004;89:4246-4253.
19. Yamaguchi T, Sugimoto T, Yano S, et al. Plasma lipids and osteoporosis in postmenopausal women. Endocrinol J 2002;49:211-217.
20. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CWGM, Papapoulos SE. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003;33:805-811.
21. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005;328:746-750.
22. Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus 2005;14:773-779.
23. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vase Biol 2001;21:817-824.
24. Hashiba H, Aizawa S, Tamura K, Kogo H. Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects. Ther Apher Dial 2006;10:59-64.
25. Tamura K, Suzuki Y, Hashiba H, Tamura H, Aizawa S, Kogo H. Effect of etidronate on aortic calcification and bone metabolism in calcitriol-treated rats with subtotal nephrectomy. J Pharmacol Sci 2005;99:89-94.
26. Tamura K, Suzuki Y, Matsushita M, et al. Prevention of aortic calcification by etidronate in the renal failure rat model. Eur J Pharmacol 2007;558:159-166.
27. Hodis HN, St. John JA, Xiang M, Cushman M, Lobo RA, Mack WJ. Inflammatory markers and progression of subclinical atherosclerosis in healthy postmenopausal women (from the Estrogen in the Prevention of Atherosclerosis Trial). Am J Cardiol 2008;101:1131-1133.
28. Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 2006;259:493-519.
29. Thompson A, Danesh J. Associations between apolipoprotein B, apoli-poprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 2006;259:481-492.
30. Charlton-Menys V, Durrington P. Apolipoproteins AI and B as therapeutic targets. J Intern Med 2006;259:462-472.
31. Lippi G, Braga V, Adami S, Guidi G. Modification of serum apolipoprotein A-I, apolipoprotein B and lipoprotein(a) levels after bisphosphonates-induced acute phase response. Clin Chim Acta 1998;271:79-87.